



Equity			% Chg	
	6-Sept	1-day	1-mth	3-mth
India				
Sensex	15,616	1.1	4.6	10.1
Nifty	4,519	1.0	3.7	8.1
Global/Regiona	al markets			
Dow Jones	13,363	0.4	(1.0)	0.7
Nasdaq	2,614	0.3	2.1	2.9
FTSE	6,313	0.7	0.1	(2.9)
Nikkei	16,157	(0.6	(4.5)	(10.5
Hang Seng	24,062	0.0	9.8	15.7

Value traded (Rs bn)	BSE	NSE
Cash	46.7	99.2
Derivatives	10.3	409.3
Total	57.0	508.5

Net inflows		Recent trends (days)		
(Rs bn)	5-Sept	-7d	-15d	-30d
FII	4.1	17.5	(29.8)	(67.1)
MF	0.7	16.0	39.9	55.9

Farmer / Omeda			% Ch	ıg
Forex / Crude	6-Sept	1day	1mth	3mth
Rs/US\$	40.8	0.0	(8.0)	(0.2)
Euro/US\$	1.4	(0.2)	(0.5)	1.8
Crude(\$/bbl)	76.5	0.2	5.6	14.3

Mkt movers (Rs)	Close	Pr. Cl.	% Chg
Top gainers			
Voltamp Trans	1,365.9	1,207.5	13.1
NIIT	144.6	130.0	11.2
Elder Pharma	440.2	399.2	10.3
Top losers			
Welspun-Gujarat	241.6	255.7	(5.6)
Patni Computer	480.1	504.8	(4.9)
Matrix Lab	246.2	257.1	(4.2)

In focus

Balaji Telefilms – Company Update	
The big picture – making inroads into films	CMP: Rs 255 Target: Rs 341 BUY
Power Grid Corporation of India – IPO Note	
Positively charged	Price band: Rs 44 – 52 SUBSCRIBE

Today's top picks HLL, NTPC, DCB, Ranbaxy, Rel Energy

News track

- Buoyant corporate performance has pushed up direct tax collection by 42% during April-August to Rs 610.3bn, compared to Rs 429.8bn during the corresponding period last fiscal. (ET)
- The Indian Bankers Association has supported the view that ICICI Bank and SBI should set up intermediate holding companies under RBI supervision. (BL)
- The DoT has turned down MTNL's application for additional GSM bandwidth in Delhi and Mumbai citing saturation of airwaves in the two metros. (ET)
- Ranbaxy, Cadila Healthcare and Sun Pharma have received USFDA approval to market the generic version of Coreg (Carvedilol) in the US. The Glaxo SmithKline drug belongs to the CVS segment and has a market size of US \$1.6bn. (ET)
- Mastek proposes to raise close to US\$ 30mn through the issue of overseas convertible bonds, ECBs or any other securities for funding acquisitions of companies in the insurance space and expansion of existing subsidiaries. (BS)
- Moser Baer Entertainment has announced its foray into Tamil film production. The Rs 20bn company has lined up six films, three in Tamil and three in Hindi to be released between November 2007 and March 2008.(BL)
- Morpen Labs is in talks with a global pharma major for contract manufacturing of multiple products. (ET)
- NIIT has entered into an agreement with China's ChongQing Information Industry Bureau to offer its training programmes through universities and colleges in ChongQing. (BL)

Source: BL: Business Line, BS: Business Standard, ET: Economic Times, FE: Financial Express

Volume shockers

(No of shares)	6-Sept	2-mth avg	Chg (x)
Monsanto India	25,600	1,497	17.1
Asian Paints	252,118	16,261	15.5
Havell's India	727,615	61,416	11.8

Delivery toppers

	Del (%)	Total vol	Cons days up
IVRCL Infra	87.7	5,663,323	6
LIC Housing	77.8	973,177	4
Infotech Enter	74.9	320,310	5



Balaji Telefilms

Company Update

CMP: Rs 255 Target: Rs 341 BUY

Ram Patnaik	Reema Deshkar
(91-22) 6612 4752	(91-22) 6612 4764
ram.patnaik@religare.in	reema.deshkar@religare.in
BSE code	532382
NSE code	BALAJITELE
Company data	

Particulars	
Market cap (Rs bn / US\$ mn)	16.6/405.5
Outstanding equity shares (mn)	65.2
52-week high/low (Rs)	278/104
6-month average daily volume	322,144

Financial snapshot

Particulars	FY07	FY08E	FY09E
Sales (Rs mn)	3,202.2	4,017.8	5,393.3
Growth (%)	14.2	25.5	34.2
Adj net profit (Rs mn)	795.4	895.2	1,073.7
Growth (%)	33.4	12.5	19.9
FDEPS (Rs)	12.2	13.7	16.5
Growth (%)	33.4	12.5	19.9
P/E (x)	20.9	18.6	15.5
RoE (%)	27.5	26.3	26.9

Risk-return profile



Shareholding pattern

(%)	Jun-07	Mar-07
Promoters	41.8	41.8
FIIs	10.9	12.9
Banks & FIs	9.4	4.6
Public	37.9	40.7

Stock performance

Returns (%)	СМР	1-mth	3-mth	6-mth
Balaji Tele	255	6.5	30.1	139.5
Sensex	15,616	4.6	10.1	24.1

Company website	www.balajitelefilms.com
-----------------	-------------------------

The big picture – making inroads into films

Balaji Telefilms (BTL) is scaling up its film production and distribution business on a war footing. Its film subsidiary, Balaji Motion Pictures (BMP), has recently acquired the international distribution rights of two T-Series movies – *Darling* (releasing today) and *Bhool Bhulaiya*, besides worldwide rights for Adlab's January 2008 release *Sarkaar Raaj*. BMP has also inked a seven-film deal with T-Series which will have an expected overall budget of over Rs 1bn. These are scheduled to release in FY09. We have raised our estimates and target price to factor in the buoyant growth in the film business. We reiterate our Buy call with a target price of Rs 341 (raised from Rs 317).

Darling releases today

Balaji Motion Pictures (BMP), the film subsidiary of Balaji Telefilms (BTL), has recently acquired the international distribution rights of two T-Series movies, namely *Darling* (starring Fardeen Khan and Esha Deol) and *Bhool Bhulaiya* (starring Akshay Kumar and Vidya Balan). Darling is being released today. The company made its entry into international distribution with the recent release of its co-produced film *Shootout at Lokhandwala*.

Acquires Sarkaar Raaj rights

BMP has also acquired the worldwide theatrical and satellite rights of Adlab's *Sarkaar Raaj* being directed by Ram Gopal Varma. Sarkaar Raaj is slated for release in January 2008 and is a sequel to Varma's 2005 release *Sarkar*.

Seven-film deal inked with T-Series

BMP has recently inked a seven-film deal with T-Series with an expected overall budget of over Rs 1bn. The deal is likely to be a mix of film co-production and distribution with the films scheduled to release in FY09.

The company has also signed co-production deals with Suniel Shetty's Popcorn Motion Pictures and Sanjay Gupta's White Feather Films. This apart, BMP plans to produce two films on its own, namely *C Company* and *Kya Kool Hain Hum 2*. The company has recently signed on directors like Abbas Mustaan, Tigmanshu Dhulia, Rohit Shetty and Apoorva Lakhia for its various projects. We have raised our estimates to build in all these new projects.

JV with Star for launch of regional programmes

BTL has entered into a joint venture with the Star group for the launch of channels in regional languages other than Hindi. The company will acquire a 49% stake in the JV, which includes the existing Star group channel 'Vijay', for an initial investment of around Rs 600mn. A new Telugu channel launch is also planned soon. BTL will produce regional-based commissioned programmes for the JV, which we believe would generate significant revenues for the company. This JV has already been factored into our estimates.



Revision of estimates

We have revised our estimates upwards to build in the buoyant growth in the film business. Although we do not have specific details on the size of each new project, we have factored in the overall budget for movies to be produced, co-produced and distributed. Our revised consolidated financial estimates for FY08 and FY09 are shown in the table below.

Estimate revision

(Rs mn)	Before r	evision	After revision	
(1/2)	FY08E	FY09E	FY08E	FY09E
Revenue	3,837.8	4,493.3	4,017.8	5,393.3
Operating Profit	1,347.2	1,507.7	1,377.2	1,657.7
Net Profit	875.2	973.7	895.2	1,073.7
EPS (Rs)	13.4	14.9	13.7	16.5

Source: Company, Religare Research

Valuation

Movie foray and JV with Star to fuel 30% revenue CAGR over FY07-FY09

We expect the company to register a 30% CAGR in its consolidated revenue over FY07-FY09. Operating profit is expected to record an 18% CAGR during the same period, with net profit clocking a 16% CAGR.

Trading at a discount to peers

The BTL stock is currently discounting its FY08 and FY09 expected earnings by 18.6x and 15.5x respectively. After considering the cash and cash equivalents of Rs 40 and Rs 45, the stock is quoting at 15.7x and 12.8x respectively. The following comparative table shows that BTL is quoting at a discount to its peer group.

Comparative valuation

	CMD/Po)	FY08E		FY09E	
	CMP(Rs)	EPS (Rs)	P/E (x)	EPS (Rs)	P/E (x)
UTV	505.0	17.5	28.8	26.2	19.3
Zee Entertainment	317.0	8.4	37.7	10.7	29.6
NDTV	372.0	5.3	70.2	7.9	47.1
Adlabs	471.0	19.8	23.8	23.8	19.8
Balaji Telefilms	255.0	13.7	18.6	16.5	15.5
Average (excl. Balaji Tele)	-	-	40.1	-	28.9

Source: Bloomberg consensus estimates, Religare Research

We raise our target price to Rs 341

As the above table shows, the average FY09E P/E multiple for these companies is 28.9x. We have assigned a P/E multiple of 18x on FY09E earnings of Rs 16.5 for BTL, which is a 38% discount to the industry average because a) BTL is predominantly present in only one media segment – television software – vis-à-vis other vertically integrated peers, and b) the upcoming JV channels are yet to be launched. We thus arrive at a fair value of Rs 296 for BTL. On including expected cash & cash equivalents of Rs 45, we arrive at a fair value of Rs 341/share.

We have raised our target to Rs 341 to build in the buoyant film business



Quality content, regional presence and film ventures will add value; Buy

Reiterate Buy


BTL has a strong presence in the mass entertainment television content segment, with programmes in Hindi as well as other regional languages. In a CAS or DTH scenario where content alone will drive subscription and advertisement revenues for broadcasters, BTL will stand to gain by virtue of its quality content and regional presence. Its film ventures through its subsidiary are expected to add significant value to its consolidated financials. We have a revised target price of Rs 341, which represents a 34% appreciation from the current price. Buy.

Recommendation history


Date	Event	Reco price	Tgt price	Reco
22-May-07	Initiating Coverage	241	317	Buy
31-Jul-07	Results Update	250	317	Buy
06-Sep-07	Results Update	255	341	Buy

Source: Religare Research

Stock performance



Source: Religare Research



Financials

Profit and Loss statement

EBITDA 936.6 1,194.9 1,377.2 1,68 Growth (%) 39.1 27.6 15.3 2 Depreciation 143.3 112.9 125.1 13 EBIT 793.3 1,082.1 1,252.2 1,52 Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 -	
EBITDA 936.6 1,194.9 1,377.2 1,68 Growth (%) 39.1 27.6 15.3 2 Depreciation 143.3 112.9 125.1 13 EBIT 793.3 1,082.1 1,252.2 1,52 Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	3.3
Growth (%) 39.1 27.6 15.3 2 Depreciation 143.3 112.9 125.1 13 EBIT 793.3 1,082.1 1,252.2 1,52 Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	4.2
Depreciation 143.3 112.9 125.1 13 EBIT 793.3 1,082.1 1,252.2 1,52 Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	7.7
EBIT 793.3 1,082.1 1,252.2 1,52 Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	0.4
Growth (%) 37.7 36.4 15.7 2 Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	2.9
Interest 0.5 0.0 - Other income 86.9 94.4 90.0 8	4.8
Other income 86.9 94.4 90.0 8	1.8
	-
EBT 879.8 1,176.4 1,342.2 1,60	5.0
	9.8
Growth (%) 41.1 33.7 14.1	9.9
Tax 283.4 381.0 446.9 53	6.1
Effective tax rate 32.2 32.4 33.3	3.3
Adj net income 596.4 795.4 895.2 1,07	3.7
Growth (%) 44.4 33.4 12.5	9.9
Shares outstanding (mn) 65.2 65.2 65.2	5.2
FDEPS (Rs) 9.1 12.2 13.7	6.5
DPS (Rs) 3.0 4.0 5.0	6.0
CEPS (Rs) 11.3 13.9 15.6	

Source: Company, Religare Research

Cash flow statement

(Rs mn)	FY06	FY07E	FY08E	FY09E
Net income	596.4	795.4	895.2	1,073.7
Depreciation	143.3	112.9	125.1	132.9
Other adjustments	-	-	-	-
Changes in WC	50.9	(126.1)	(206.4)	(398.5)
Operating cash flow	790.6	782.2	813.9	808.1
Capital expenditure	(111.6)	(108.7)	(50.0)	(50.0)
Investments	(504.7)	(357.9)	(500.0)	(300.0)
Other investing inc/(exp)	-	-	-	-
Investing cash flow	(616.3)	(466.5)	(550.0)	(350.0)
Free cash flow	174.3	315.7	263.9	458.1
Issue of equity	27.4	-	-	-
Issue/repay debt	-	-	-	-
Dividends paid	(220.7)	(294.2)	(367.8)	(441.3)
Others	37.7	29.8	20.0	10.0
Financing cash flow	(155.6)	(264.5)	(347.8)	(431.3)
Beg. cash & cash eq	108.4	127.1	178.3	94.5
Chg in cash & cash eq	18.8	51.2	(83.9)	26.8
Closing cash & cash eq	127.1	178.3	94.5	121.3

Source: Company, Religare Research

Balance sheet

(Rs mn)	FY06	FY07E	FY08E	FY09E
Cash and cash eq	127.1	178.3	94.5	121.3
Accounts receivable	714.4	815.9	1,001.7	1,344.6
Inventories	207.4	236.9	319.2	428.5
Others current assets	248.7	284.1	356.4	478.4
Current assets	1,297.6	1,515.2	1,771.8	2,372.9
LT investments	1,642.1	2,000.0	2,500.0	2,800.0
Net fixed assets	309.2	303.6	228.5	145.6
CWIP	8.6	10.0	10.0	10.0
Total assets	3,257.4	3,828.7	4,510.3	5,328.5
Payables	199.7	228.1	286.2	384.2
Others	292.2	304.0	380.1	457.9
Current liabilities	491.9	532.1	666.3	842.1
LT debt	-	-	-	-
Other liabilities	125.2	155.0	175.0	185.0
Equity capital	130.4	130.4	130.4	130.4
Reserves	2,509.9	3,011.1	3,538.6	4,171.0
Net Worth	2,640.3	3,141.5	3,669.0	4,301.4
Total liabilities	3,257.4	3,828.7	4,510.3	5,328.5
BVPS (Rs)	40.5	48.2	56.3	66.0

Source: Company, Religare Research

Financial ratios

	FY06	FY07E	FY08E	FY09E
EBITDA margin (%)	33.4	37.3	34.3	30.7
EBIT margin (%)	28.3	33.8	31.2	28.3
Net profit margin (%)	21.3	24.8	22.3	19.9
FDEPS growth (%)	14.1	33.4	12.5	19.9
Receivables (days)	93.0	93.0	91.0	91.0
Inventory (days)	27.0	27.0	29.0	29.0
Payables (days)	26.0	26.0	26.0	26.0
Current ratio (x)	2.6	2.8	2.7	2.8
Interest coverage (x)	-	-	-	-
Debt/equity ratio (x)	-	-	-	-
ROE (%)	24.5	27.5	26.3	26.9
ROCE (%)	23.4	26.2	25.1	25.8
ROAE (%)	31.2	35.7	35.1	36.6
EV/Sales (x)	5.9	5.2	4.1	3.1
EV/EBITDA (x)	16.2	12.9	11.3	9.5
P/E (x)	27.9	20.9	18.6	15.5
P/BV (x)	6.3	5.3	4.5	3.9
P/CEPS (x)	22.5	18.3	16.3	13.8

Source: Company, Religare Research

Power Grid Corporation of India

IPO Note

Price Band : Rs 44 – 52 SUBSCRIBE

Vinod Nair	Ronald Siyoni
(91-22) 6612 4731	(91-22) 6612 4615
nair.vinod@religare.in	ronald.siyoni@religare.in

IPO fact sheet

Particulars	_
Issue opens	10 Sep 2007
Issue closes	13 Sep 2007
Price band (Rs)	44 – 52
Number of shares (mn)	573.9
Issue size (Rs bn)	25.3 – 29.8
Pre-issue equity (Rs bn)	38.3
Post-issue equity (Rs bn)	42.1
Financial year ending	March

Issue details

Number of shares	(mn)
Net issue to public	559.9
Employee reservation	14.0
QIB portion	280.0
HNI portion	84.0
Retail portion	196.0

Financial snapshot

Particulars	FY05	FY06	FY07
Sales (Rs bn)	25.1	32.1	37.2
Growth (%)	3.2	27.8	15.9
EBITDA (Rs bn)	20.1	25.9	30.8
Growth (%)	1.6	28.7	18.9
Adj. net income (Rs bn)	7.9	10.1	12.3
FDEPS (Rs)	2.4	3.0	3.2
EV/EBITDA (x)	6.9	5.9	5.1
ROCE (%)	7.4	8.6	8.6

Shareholding pattern

(%)	Pre-issue	Post-issue
Promoters	100	86.4
Others	-	13.6

Company website	www.powergridindia.com
-----------------	------------------------

Positively charged!

Ideal play on India's fast-growing power transmission sector

Investment rationale

- Monopoly player in India's transmission infrastructure sector, with ownership of electrical transmission lines covering 61,875 circuit kilometres and 106 substations.
- Investments of ~Rs 10.3tn planned in India's power sector to raise generation capacity by over 65% from 132,329MW to 219,992MW over the 11th plan period. PGCIL plans to concurrently raise transmission capacity 2.5 times from 14,100MW to 37,150MW by 2012.
- Impeccable implementation record the company surpassed capacity addition targets during the eight, ninth and tenth plans to add 9,724 circuit km, 12,436 circuit km and 19,172 circuit km of lines respectively.
- Very strong operational efficiency with system availability of 98-99%.
- Assured 14% ROE towards its capacity investment as per the tariff structure fixed by Central Electricity Regulatory Commission (CERC).

Key concerns

- Entry of private players would erode market share.
- The tariff set by CERC caps the company's return generating capacity. There is also the risk of a tariff reduction during the scheduled re-pricing in April 2009.

Valuation


At the lower band of Rs 44, PGCIL is available at a P/E of 17x on FY07 and 10x on FY08E (based on Q1FY08 annualised EPS) and at 20x and 12x at the upper band of Rs 52 (diluted basis). The current BV/share is Rs 30.5 adjusted for the dilution and Q1FY08 PAT; the Price/BV is thus 1.4x and 1.7x on Rs 44 and Rs 52 respectively. Subscribe.





Source: Religare Research

P/E multiple (x)



Source: Religare Research

Financials

Profit and Loss statement

(Rs bn)	FY04	FY05	FY06	FY07
Revenues	24.4	25.1	32.1	37.2
Growth (%)	21.0	3.2	27.8	15.9
EBITDA	19.8	20.1	25.9	30.8
Growth (%)	29.2	1.6	28.7	18.9
Depreciation	6.1	6.4	7.4	8.3
EBIT	13.8	13.7	18.5	22.5
Growth (%)	28.3	(0.3)	34.6	22.0
Interest	9.9	8.1	9.5	11.4
Other income	3.7	3.2	3.4	3.6
EBT	7.6	8.8	12.4	14.7
Growth (%)	(1.2)	16.5	41.0	18.6
Tax	(0.3)	1.2	1.6	2.5
Effective tax rate	(4.5)	13.9	12.9	17.2
Adj net income	7.5	7.9	10.1	12.3
Growth (%)	14.0	5.0	28.4	21.8
Shares outstanding (bn)	3.1	3.2	3.6	3.8
FDEPS (Rs)	2.6	2.4	3.0	3.2
DPS (Rs)	0.5	0.7	1.0	1.1
CEPS (Rs)	4.5	4.4	5.0	5.4

Source: Company, Religare Research

Cash flow statement

(Rs bn)	FY04	FY05	FY06	FY07
Net income	7.5	7.9	10.1	12.3
Depreciation	6.1	6.4	7.4	8.3
Other adjustments	22.0	8.2	8.5	40.0
Changes in WC	6.3	4.5	8.1	11.7
Operating cash flow	41.8	27.0	34.1	72.2
Capital expenditure	(15.5)	(33.4)	(30.8)	(65.6)
Investments	(1.1)	(0.3)	(1.1)	1.7
Other investing inc/(exp)	0.0	0.0	0.0	0.0
Investing cash flow	(16.7)	(33.7)	(31.9)	(63.9)
Free cash flow	25.1	(6.7)	2.2	8.4
Issue of equity	0.0	1.3	4.2	2.0
Issue/repay debt	(16.2)	5.7	(3.1)	(0.0)
Dividends paid	(1.4)	(2.1)	(3.5)	(4.3)
Others	0.0	0.0	0.0	0.0
Financing cash flow	(17.6)	4.9	(2.3)	(2.3)
Beg. cash & cash eq	0.2	7.8	6.0	5.9
Chg in cash & cash eq	7.6	(1.7)	(0.1)	6.1
Closing cash & cash eq	7.8	6.0	5.9	12.0

Source: Company, Religare Research

Recommendation history

Date	Event	Reco price	Tgt price	Reco
06-Sep-07	IPO Note	44-52	NA	Subscribe

Source: Religare Research

Balance sheet

(Rs bn)	FY04	FY05	FY06	FY07
Cash and cash eq	7.8	6.0	5.9	12.0
Accounts receivable	4.8	5.7	4.4	4.9
Inventories	2.0	1.8	1.8	1.8
Others current assets	16.6	15.0	17.5	16.4
Current assets	31.1	28.6	29.6	35.1
LT investments	20.0	20.3	21.4	19.7
Net fixed assets	165.2	177.2	212.8	251.9
CWIP	22.5	35.8	36.5	60.8
Total assets	238.9	261.9	300.3	367.5
Payables	20.7	24.7	31.8	40.0
Others	3.7	3.4	5.5	8.3
Current liabilities	24.4	28.1	37.2	48.4
LT debt	122.7	133.9	150.3	193.3
Other liabilities	10.9	11.4	14.1	18.8
Equity capital	30.7	32.0	36.2	38.3
Reserves	50.2	56.4	62.5	68.8
Net Worth	81.0	88.5	98.7	107.0
Total liabilities	238.9	261.9	300.3	367.5
BVPS (Rs)	26.3	27.6	27.2	28.0

Source: Company, Religare Research

Financial ratios

	FY04	FY05	FY06	FY07
EBITDA margin (%)	81.4	80.1	80.7	82.8
EBIT margin (%)	56.5	54.6	57.5	60.5
Net profit margin (%)	32.4	30.2	33.7	32.8
FDEPS growth (%)	0.0	(8.0)	26.2	6.8
Receivables (days)	70.6	81.8	49.3	47.4
Inventory (days)	29.1	26.4	20.2	17.8
Payables (days)	306.1	353.0	355.8	387.0
Current ratio (x)	1.3	1.0	0.8	0.7
Interest coverage (x)	1.4	1.7	2.0	2.0
Debt/equity ratio (x)	1.5	1.5	1.5	1.8
ROE (%)	10.3	8.8	10.9	11.5
ROCE (%)	9.1	7.4	8.6	8.6
ROAE (%)	0.0	6.4	7.0	7.1
EV/Sales (x)	6.3	5.5	4.8	4.2
EV/EBITDA (x)	7.7	6.9	5.9	5.1
P/E (x)	17.1	18.6	14.7	13.8
P/BV (x)	1.7	1.6	1.6	1.6
P/CEPS (x)	9.7	10.1	8.7	8.2

Source: Company, Religare Research



Recommendation tracker

Date	Company	Report type	Stock price (Rs)	Target (Rs)	Reco
30-Jul-07	PVR Cinemas	Results Update	209	277	BUY
30-Jul-07	Shringar Cinemas	Results Update	60	75	BUY
30-Jul-07	Apollo Tyres	Results Update	391	498	BUY
30-Jul-07	Federal Bank	Results Update	352	434	BUY
31-Jul-07	RPG Cables	Results Update	48	87	BUY
31-Jul-07	Balaji Telefilms	Results Update	250	317	BUY
01-Aug-07	Nava Bharat Ventures	Results Update	198	302	BUY
01-Aug-07	K S Oils	Results Update	55	68	BUY
01-Aug-07	Bank of Baroda	Results Update	300	343	BUY
01-Aug-07	Dishman Pharmaceuticals and Chemicals	Results Update	315	357	HOLD
01-Aug-07	Cadila	Results Update	351	416	BUY
01-Aug-07	Divi's Laboratories	Results Update	6,692	6,330	HOLD
02-Aug-07	Maruti Udyog	Results Update	821	945	BUY
02-Aug-07	Sangam (India)	Results Update	56	95	BUY
02-Aug-07	KPR Mills	IPO Note	225-265	NA	AVOID
02-Aug-07	Riddhi Siddhi Gluco Biols	Results Update	265	365	BUY
06-Aug-07	Mahindra and Mahindra	Results Update	678	990	BUY
06-Aug-07	Cinemax	Results Update	142	189	BUY
06-Aug-07	Parsvnath Developers	Initiating Coverage	326	512	BUY
08-Aug-07	Wipro Technologies	Company Update	459	595	HOLD
09-Aug-07	Punjab National Bank	Analyst Meet Note	521	610	BUY
13-Aug-07	Bajaj Auto	Company Update	2,319	2,748	BUY
13-Aug-07	IVRCL Infrastructures & Projects	Initiating Coverage	381	488	BUY
13-Aug07	Inox Leisure	Results Update	121	120	SELL
14-Aug-07	Madhucon Projects	Company Update	247	332	BUY
16-Aug-07	Riddhi Siddhi Gluco Biols	Company Update	270	365	BUY
17-Aug-07	Jindal Drilling and Industries	Initiating Coverage	754	1,056	BUY
20-Aug-07	Motilal Oswal Financial Services	IPO Note	725 – 825	NA	SUBSCRIBE
20-Aug-07	Time Technoplast	Initiating Coverage	525	736	BUY
22-Aug-07	Sujana Towers	Company Update	122	157	BUY
22-Aug-07	Prism Cement	Initiating Coverage	51	81	BUY
24-Aug-07	PVR Cinemas	Company Update	179	277	BUY
27-Aug-07	Cipla	Company Update	171	191	HOLD
27-Aug-07	IT People	FPO Note	40	30-32	NA
28-Aug-07	Ashok Leyland	Company Update	35	48	BUY
29-Aug-07	Parsvnath Developers	Company Update	287	512	BUY
30-Aug-07	Jagran Prakashan	Initiating Coverage	551	662	BUY
30-Aug-07	Deccan Chronicle	Initiating Coverage	228	273	BUY
30-Aug-07	HT Media	Initiating Coverage	211	232	NEUTRAL
03-Sep-07	Central Bank of India	Company Update	125	144	HOLD
04-Sep-07	Maruti Udyog	Company Update	881	945	BUY
05-Sep-07	Parsvnath Developers	Company Update	316	512	BUY
05-Sep-07	MindTree Consulting	Initiating Coverage	589	556	SELL
05-Sep-07	Shri Lakshmi Cotsyn	Initiating Coverage	104	210	BUY
06-Sep-07	Power Grid Corporation of India	IPO Note	44 – 52	NA	SUBSCRIBE
07-Sep-07	Balaji Telefilms	Company Update	255	341	BUY



Market trends

BSE sectoral indices



Emerging markets

Country			% Chg		
	6-Sept	1-day	1-mth	3-mth	6-mth
Brazil	54,569	0.3	1.4	4.8	27.9
Shanghai	5,326	(1.3)	14.5	36.9	83.9
Hong Kong	24,062	0.0	9.8	15.7	27.2
India	15,616	1.1	4.6	10.1	24.1
South Korea	1,884	(0.3)	1.3	7.5	33.5
Taiwan	9,056	0.4	2.2	8.4	21.1

FII statistics

(US\$ mn)	1-day	WTD	MTD	YTD
India	100.5	286.6	286.6	8,660.6
South Korea	(441.8)	(256.5)	(256.5)	(14,273.5)
Taiwan	209.3	350.0	350.0	2,322.2
Thailand	(1,141.5)	10.2	10.2	2,977.7



Events calendar

Board meetings

Sep	tember 7	8		9	
	Alcobex Met - Results		Lloyds Metals - Issue of warrants		-
	Kusum Elect Results		Sidharth Tub - Results		
	Isibars - Results				
10		11		12	
	Dhanprayog – Results		Areva T&D – Results		Asian Oilfie - General
					Gulshan Poly - General
13		14		15	
	Adlabs Films – Divident, Results				



Trade data

Institutional bulk deals


Scrip	Client	Buy/Sell	Quantity	Avg Price (Rs)
Amtekauto-Roll Sett	Merrill Lynch Capital Markets Espana SA Svb	В	2,158,015	359.5
Gokaldas Exp	DSP Merrill Lynch Capital	S	203,350	253.0
Goldstone Tech	ILFS Investsmart PMS	В	100,000	140.0
Havell India	PCA India Infrastructure Equity Open	В	320,622	501.0
IVRCL Inf Pr	Capital Research And Management Co	В	3,164,853	400.0
IVRCL Inf Pr	Crown Capital	S	2,547,060	400.0
Ivrcl Infra & Proj	Capital Research & Mgmt Co A/C Small Cap World	В	1,260,000	399.7
Jain Irrigation Systems L	Merrill Lynch Capital Markets Espana SA Svb	В	2,842,916	484.0
Rico Auto Industries	HDFC Core & Satelte Fund	S	636,069	34.4
Shree Precoated Steels	Merrill Lynch Capital Markets Espana SA Svb	В	2,330,048	358.8
Unity Infra	BSMA	В	100,000	605.0

Source: BSE

Insider trading

			Shares		Post-transaction	
Scrip	Acquirer/Seller	Buy/Sell		transacted		holding
			Qty	%		
Ansal Housing & Construction	J P Morgan Securities & Pacs	В	13000	0.07	841530	5.04
Bhagwati Banquets & Hotels	Lotus Global Investments	В	1000000	3.41	2000000	6.83
CCS Infotech	M A Hasan Abdul Kader	В	50000	-	418100	4.16
Crystal Software Solutuions	Richline Finvest	В	90691	1.81	358772	7.18
Crystal Software Solutuions	Kaushal N Shah	В	30000	0.6	613065	12.28
Gokaldas Exports	FID Fds (M) & FID Aus India Fund	S	1500000	4.36	468599	1.36
I-Flex Solutions	Olivier Trancart	В	20000	-	-	-
ICSA (India)	Goldman Sachs Investments (M)	В	60000	-	-	-
ICSA (India)	Goldman Sachs Investments (M)	S	158355	-	298177	3.76
K Sera Sera Productions	Macquarie Bank	S	101578	0.52	907554	4.65
Kotak Mahindra Bank	Ashish Khetan	В	7590	-	7590	-
Kotak Mahindra Bank	Vivek Anand P S	В	3007	-	4904	-
Lupin	Dr K U Mada	В	25	-	325	-
Lupin	Parari A Patil	В	100	-	1650	-
Multi Arc India	Sunidhi Securities & Finance	В	190000	2.34	620000	7.63
Multi Arc India	Jasvantlal Chhotalal & Co	S	190000	2.34	-	-
Satyam Computer Services	V Murali	S	1000	-	-	-
Satyam Computer Services	K Sriram	S	1500	-	-	-
Splash Media Works	Manoj Meher	S	20000	1.6	-	-
United Phosphorus	SBI Mutual Fund	S	50000	0.02	5400686	2.87
Venus Remedies	Sonata Investments	В	145084	1.72	941405	11.17

Source: BSE



RELIGARE RESEARCH

Fundamental Research			
Amitabh Chakraborty, CFA, FRM	President - Equity	amitabh.chakraborty@religare.in	(91-22) 6612 4603
Piyush Parag	Auto, Auto Ancillaries, Shipping	piyush.parag@religare.in	(91-22) 6612 4730
Abhishek Agarwal	Agri-commodities, Banking	abhishek.a@religare.in	(91-22) 6612 4753
Dinesh Shukla	Agri-commodities, Banking	dinesh.shukla@religare.in	(91-22) 6612 4739
Ram Patnaik	Agri-commodities, Media, FMCG	ram.patnaik@religare.in	(91-22) 6612 4752
Reema Deshkar	Agri-commodities, Media, FMCG	reema.deshkar@religare.in	(91-22) 6612 4764
Vinod Nair	Capital Goods, Engineering, Metals, Media	nair.vinod@religare.in	(91-22) 6612 4731
Ronald Siyoni	Capital Goods, Engineering, Power	ronald.siyoni@religare.in	(91-22) 6612 4615
Dalpat Mehta	Cement, Textiles	dalpat.mehta@religare.in	(91-22) 6612 4696
Anurag Purohit	Information Technology, Telecom	anurag.purohit@religare.in	(91-22) 6612 4795
Hitesh Punjabi	Information Technology, Telecom	hitesh.punjabi@religare.in	(91-22) 6612 4769
Suman Memani	Mid-caps, Construction, Realty	suman.memani@religare.in	(91-22) 6612 4736
Sudeep Anand	Oil & Gas, Chemicals	sudeep.anand@religare.in	(91-22) 6612 4670
Bhawana Verma	Oil & Gas, Chemicals	bhawana.verma@religare.in	(91-22) 6612 4713
Alok Dalal	Pharmaceuticals	alok.dalal@religare.in	(91-22) 6612 4750
Technical Research			
Birendrakumar Singh		birendrakumar.singh@religare.in	(91-22) 6612 4657
Vasant Joshi		vasant.joshi@religare.in	(91-22) 6612 4614
Amit Shitut		amit.shitut@religre.in	(91-20) 3024 0376
Kalpana Kabra		kalpana.kabra@religare.in	(91-33) 3051 0947
Derivatives Research			
Anil Gupta		anil.g@religare.in	(91-22) 6612 4661
Samir Badami		samir.badami@religare.in	(91-22) 6612 4637
Somendra Agarwal		somendra.agarwal@religare.in	(91-22) 6612 4767
Production			
Anisha deSa		anisha.desa@religare.in	(91-22) 6612 4729
R Murali		r.murali@religare.in	(91-22) 6612 4674
Rajesh Mhatre		rajesh.mhatre@religare.in	(91-22) 6612 4728
Administration			
Administration Shraddha Hosalkar		shraddha.hosalkar@religare.in	(91-22) 6612 4680



Recommendation parameters

Large-caps*	> 10%	< -5%	⊋ ⊱
	BUY	SELL	solu
Mid-caps**	> 25%	< 10%	ns ute

*Market cap over US\$ 1bn **Market cap less than US\$ 1bn

Religare Securities

Mumbai: 3rd Floor, Dheeraj Arma, Anant Kanekar Marg, Bandra (East), Mumbai-400 051. Phone: +91 22 66124600 Fax- 66124781

New Delhi: 19, Nehru Place, New Delhi - 110019, Phone: +91 11 30815100.

Disclaimer

Religare Securities Limited (Religare) has two independent equity research groups: Institutional Equities (Institutional Equity Research) and Priority Client Group (Religare Research). Religare Institutional Equity Research is aimed to service the institutional clients of Religare Securities Limited including the Portfolio Management Services of Religare whereas Religare Research is published with a view to service all segments of clients including Retail, HNIs and Institutional clients and PMS.

This document has been prepared by Religare Securities Limited – Priority Client Group. Affiliates of Religare-PCG may have issued other reports that are contrary with and reach different conclusion from the information presented in this report. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating and target price of the Institutional Equities Research Group of Religare Securities Limited.

We are not soliciting any action based upon this material. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Religare-PCG. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Religare-PCG will not treat recipients as customers by virtue of their receiving this report. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable. It should be noted that the information contained herein is from publicly available data or other sources believed to be reliable. Neither Religare, nor any person connected with it, accepts any liability arising from the use of this document.

This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for any investment decision. The investment discussed or views expressed may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Opinions expressed are our current opinions as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we would endeavor to update the information herein on a reasonable basis, Religare, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent Religare and affiliates from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Religare and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Religare and its affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall Religare, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Copy right in this document vests exclusively with Religare. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from Religare. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Analyst's holding in the stocks mentioned in the report: **NIL**.